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Abstract 
Background: For Europe as a whole, data on internal exposure to environmental chemicals do 
not yet exist. Characterization of the internal individual chemical environment is expected to 
enhance understanding of the environmental threats to health.  
Objectives: We developed and applied a harmonized protocol to collect comparable human 
biomonitoring data all over Europe.  
Methods: In 17 European countries, we measured mercury in hair and cotinine, phthalate 
metabolites and cadmium in urine of 1844 children (5-11 years) and their mothers. Specimens 
were collected over a 5 month period in 2011-2012. We obtained information on personal 
characteristics, environment, and life style. We used the resulting database to compare 
concentrations of exposure biomarkers within Europe, to identify determinants of exposure, and 
to compare exposure biomarkers with health-based guidelines.  
Results: Biomarker concentrations showed a wide variability in the European population. 
However, levels in children and mothers were highly correlated. Most biomarker concentrations 
were below the health-based guidance values. 
Conclusions: We have taken the first steps to assess personal chemical exposures in Europe as a 
whole. Key success factors were the harmonised protocol development, intensive training and 
capacity building for field work, chemical analysis and communication, as well as stringent 
quality control programs for chemical and data analysis. Our project demonstrates the feasibility 
of a European-wide human biomonitoring framework to support the decision-making process of 
environmental measures to protect public health. 
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Introduction 
Human biomonitoring (HBM) measures the levels of environmental chemicals or their 
metabolites in easily accessible body fluids and tissues (Angerer et al. 2006), and reflects all 
routes of uptake - oral, dermal, inhalative - and all relevant sources. The power of HBM to 
identify spatial and temporal trends in human exposures has contributed successfully to initiate 
policy measures and to focus on protection of susceptible populations such as children and 
pregnant mothers. The ban of lead from gasoline was triggered by elevated blood lead levels in 
the National Health and Nutrition Examination Survey (NHANES) (Pirkle et al. 1994). Results 
of the German Environmental Survey (GerES) led to recommendations to avoid mercury 
containing amalgam teeth fillings in children (Becker et al. 2013) and contributed to  restriction 
of phthalate use in plastics (Goen et al. 2011). Increasing levels of polybrominated 
diphenylethers (PBDEs) in maternal milk samples of Sweden have lead to the gradual phasing 
out of lower PBDEs (Meironyte et al. 1999).  
Experience with human biomonitoring in the general population differs among European 
countries, with long standing traditions in countries such as Germany (Becker et al. 2008), 
France (Frery et al. 2012), the Czech Republic (Cerna et al. 2012), Belgium (Flanders)(Schoeters 
et al. 2011), Spain (Perez-Gomez, 2013) while other countries have no experience at all.  
The ‘European Environment and Health Action Plan’ (Communication from the Commission, 
2004) prioritized the need to harmonize HBM in Europe to allow comparison of data among 
countries and provide tools for follow-up of temporal and spatial trends in chemical exposures. 
The preparation of the protocol, including the selection of chemicals, study populations, started 
in 2005 with the Expert team to Support BIOmonitoring in Europe (ESBIO) project. With the 
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funding of the Consortium to Perform Human Biomonitoring on a European Scale (COPHES) 
and its demonstration project DEMOCOPHES, the feasibility of a harmonized HBM approach 
was tested(Human Biomonitoring in Europe, 2012). COPHES designed the final protocol and 
made justified choices for exposure biomarkers, sample size and recruitment strategy. 
DEMOCOPHES allowed 17 European countries to put this protocol into practice. Selected 
chemicals included phthalates that are present in some consumer products and foodpackaging 
(Koch and Calafat 2009), mercury and cadmium as ubiquitous developmental toxicants of 
concern (Grandjean and Landrigan 2006), urinary cotinine (Avila-Tang et al. 2013) as a 
biomarker for exposure to cigarette smoke; urinary creatinine was included as a measure for 
urine dilution. Young children and mothers of childbearing age were selected as vulnerable age 
groups. Mercury in hair (Budtz-Jorgensen et al. 2004) and urinary cadmium (Akerstrom et al. 
2013) are markers of chemicals that accumulate in the body over a longer time period, urinary 
phthalate metabolites (Wittassek et al. 2011) and cotinine (Avila-Tang et al. 2013) measured in 
spot urine samples represent short-time exposure.  
Methods 
Study design and participants 
The cross-sectional survey was designed to include 120 children (5-11 years) and their mothers 
in each country, with 60 mother-child pairs in Cyprus and Luxembourg due to the countries’ 
smaller populations. We sampled the children and mothersbetween September 2011 and 
February 2012, either through schools or population registries. These were convenience samples 
with equal shares in an urban and a rural location as defined according to regional standards. We 
included only healthy children and mothers (no metabolic disturbances), who had sufficient 
knowledge of the local language and had been living at least for 5 years at the sampling location. 
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Details and rationale for the study design are reported by Becker et al. (Becker et al. 2014).  The 
sample size allowed us to estimate preliminary country specific reference values (Poulsen et al. 
1997) and a minimally important difference in mean biomarker values of 30% between countries 
(α= 0.05, β= 0.80). Field workers from the national study centers were trained, instructions were 
provided centrally and adapted at national level to the language, cultural conventions, ethical and 
legal requirements. Information on characteristics of the study population and potential 
determinants of internal exposure were obtained through personalised interviews using 
questionnaires. Standard Operation Procedures (SOPs) to collect hair and morning urine samples 
were implemented (Becker et al. 2014). The study was approved by ethics committees in each 
country (list of ethics committees per country: see Supplemental Material, Table S1); mothers 
and children gave written informed consent or assent, respectively. All procedures followed the 
national data protection requirements including notification to data protection authorities.  
Chemical analysis 
We established a Quality Assurance Program to guarantee the quality and comparability of 
analytical results among laboratories (Schindler et al. 2014). Each participating laboratory 
received SOPs for sampling, sample conservation and chemical analysis (Becker et al. 2014; 
Schindler et al. 2014). We organized two Interlaboratory Comparison Investigations and two 
External Quality Assessment Schemes (ICI/EQUAS) with native control material (hair, urine) 
sent to all laboratories willing to participate. For the evaluation of the ICIs we calculated 
consensus values as the mean of the results of the participating laboratories (after exclusion of 
outliers). For the evaluation of the EQUAS, we calculated assigned values (target values) from 
the results of experienced, renowned reference laboratories. Laboratories were defined as 
‘qualified laboratories’ if they participated successfully in at least one ICI and one EQUAS 
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round or in two EQUAS rounds (Schindler et al. 2014). The number of laboratories that qualified 
for each analyte was: mercury, 15; cotinine, 9; cadmium, 14; phthalate metabolites (MEHP, 
5OH-MEPH, 5oxo-MEHP, MEP, MBzP, MnBP, MuBP), 7 and creatinine, 14.  
Database management and statistical analysis 
National data centers applied uniform rules for database construction by using one centrally 
developed code book with pre-defined variable names, unities, formats and coding rules. Quality 
controls on the data were performed with centrally developed programs (SAS or SPSS). These 
strict and uniform rules for database construction allowed us to pool all country-specific data into 
one central European database. We used SAS software, version 9.3 (SAS Institute Inc.) for 
analysis of the central database. We replaced values below the LOQ by ½LOQ and transformed 
biomarker data to natural log-transformed concentrations (ln). We excluded samples with 
creatinine concentrations below 300 mg/L or above 3000 mg/L from statistical analysis 
(WHO,1996). We calculated weighted geometric means (GM) (95% confidence interval, 
95%CI) and 90th percentiles (P90) (95% CI) so that the countries were equally represented except 
for Cyprus and Luxembourg that contributed only half. Using multiple mixed regression models 
with country as random factor, we identified determinants of exposure biomarkers by including 
pre-specified confounders and significant covariates (P<0.25 from univariate model to enter and 
P<0.05 to stay) in a stepwise model. We expressed urinary biomarkers in µg/L with urinary 
creatinine included as confounder. We expressed results as % change (95% CI) of biomarker 
concentration for change of the determinant, after adjustment for all other variables in the model. 
Detailed methodology and full models are given in the Supplemental Material (“Identification of 
determinants of exposure; Comparison of results between countries” and Table S2). 
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To compare biomarker values among countries, we compared the GM of a country with the 
European GM by mixed linear regression analysis, after adjustment for pre-specified 
confounders (Figure 1). To visualize similarity between the biomarker levels and between 
different countries and/or mothers and children from the same country a heat map was generated 
using the clustergram function (Matlab, The MathWorks Inc. Massachusetts, USA) (Figure 2). 
Hierarchical clustering with Euclidean distance metric and average linkage was used to generate 
the hierarchical tree. Prior to analysis the GM of each country was divided by the European GM. 
The ratio was calculated for mothers and children separately and was logarithmically 
transformed (log2 base) to obtain symmetry around 0 (= log2(1)). The nearest-neighbor method 
was applied to impute missing data.  
To put the results in a health risk context, we calculated the proportion of individuals with levels 
above health-based guidance values (Aylward et al. 2009a;Aylward et al. 2009b;Hays et al. 
2008;Joint Expert Committee on Food Additives 2003;Schulz et al. 2012). 
Results  
Determinants of biomarker concentrations  
Descriptive statistics of 1844 children and mothers included in the study are given in Table 1. 
Participants were equally recruited according to predefined strata of gender, age and sampling 
area in each country. Descriptive statistics of the biomarkers and multiple regression models are 
given in the Supplemental Material (Tables S3-S19).  
Fish consumption was the major predictor of mercury levels in hair, both in children and in 
mothers (Supplemental Material, Tables S4 and S5). Consumption of sea fish, shellfish or fresh 
water fish in the past four weeks independently contributed to mercury levels in the body. In 
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multiple regression models, frequent (several times/week) compared to sporadic (once/week or 
less) sea fish consumption was associated with 46% (95% CI: 26-69%) higher mercury levels in 
children and 51% (34-71%) in mothers; shellfish with 56% (35-79%) in children and 38% (24-
55%) in mothers, fresh water fish with 23% (8-39%) in children and 23% (11-37%) in mothers. 
The GM mercury levels of mothers were higher than those of the children (Table 2), but levels of 
mothers and children were higly correlated (Spearman’s r = 0.72, p<0.001, n= 1833). Older 
mothers had 15% (5-24%) higher levels compared to the youngest age group (Supplemental 
Material, Table S5). Younger children of 5-8 years showed 8% (0-17%) higher levels compared 
to the older group of 9-11 years (Supplemental Material, Table S4). Participants from families 
with a higher educational level (tertiary vs. primary education) had 19% (4-31%) higher levels of 
mercury in children and 25% (13-36%) in mothers  
Cadmium levels in mothers were significantly higher in active smoking mothers and this was 
independent of age. The GM were higher in mothers than in children (Table 2). Older mothers 
had 25% (18-32%) higher levels than younger mothers (Supplemental Material, Table S9). 
Levels in mothers and children showed a low but significant correlation (Spearman’s r = 0.24, 
p<0.001, n= 1660). After adjustment for age and smoking, mothers from families with a tertiary 
education had 34% (17-54%) lower levels compared to those with a primary education. In 
children, except for age and creatinine, no significant determinants were identified 
(Supplemental Material, Table S8).  
The urinary levels of MEHP, 5OH-MEHP and 5oxo-MEH were highly correlated (Pearson’s 
r>0.70), and thus their sum was used in the analyses. The GM of urinary phthalate metabolites 
(except MEP, related to PCP use) were higher in children than in mothers (Table 2). Phthalate 
levels of mothers and children were significantly correlated (p<0.001): Spearman’s r ranged 
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between 0.40 and 0.49.  Multiple regression models (Table 3) showed that younger children of 5-
8 years showed higher levels compared to the older group of 9-11 years. Participants from 
families reporting to have PVC floors or walls, had significantly increased levels of MBzP and 
MiBP in children and mothers and of  MnBP in children (Table 3 and 4). A small effect of recent 
renovation works on MiBP was seen in mothers who reported renovation in the house in the past 
two years. Frequent use of personal care products (PCP) increased urinary MEP levels in 
mothers and children and urinary MiBP levels in children. Unexpectedly, urinary levels of 
DEHP metabolites and MnBP in mothers were lower in high PCP users. High consumption of 
ice cream was associated with higher urinary levels of DEHP metabolites and  MBzP levels in 
children and with higher MnBP and  MBzP levels in mothers. High consumption of chewing 
gum was related to higher urinary levels of DEHP metabolites in children and to higher MEP 
levels in mothers. After adjustment for confounders and significant covariates, educational level 
was still a predictor of phthalate biomarkers, i.e. significantly higher urinary levels were found 
for DEHP metabolites in mothers from families with a primary education, for MiBP (mothers) 
and MEP (children) in families with secondary education and for MnBP (children) in families 
with tertiary education.  
In mothers, the effect of active smoking on cotinine levels was dominant (Supplemental 
Material, Table S7). Levels in mothers and children correlated strongly (Spearman’s r = 0.71, 
p<0.001, n= 1777). The younger children of 5-8 years showed 16% (8-25%) higher levels 
compared to the older group of 9-11 years (Supplemental Material, Table S6). In children, 
environmental tobacco smoke (ETS) at home was the strongest predictor. Compared to children 
who were never exposed to ETS at home, children with daily exposure had 5 times higher values 
(+504% (429-593%)) and children with less than daily exposure had almost double values 
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(+181% (155-211%)). Exposure to ETS in other places than home resulted in 19% (10-29%) 
higher values. In comparison with children from families with a tertiary education, those with a 
secondary education had 20% (10-30%) higher cotinine levels in urine and those with primary 
education had 49% (29-72%) higher values.  
The geographical aspect 
Residence in urban or rural area did not show up as a significant determinant of internal exposure 
at the EU level. Only mercury in hair showed, independently of fish consumption, higher levels 
in urban areas compared to rural areas: 35% (23-47%) higher in children and 30% (19-41%) in 
mothers (Supplemental Material, Table S4 and S5).  
The average biomarker concentrations varied significantly among the European countries. This 
holds for the unadjusted data (Supplemental Material, Table S20-S35) and for data after 
adjustment for age, gender and weighing for equal group sizes (Figure 1). The average biomarker 
concentrations of mercury in hair of Spanish and Portugese children were respectively 6 and 7 
times higher than the European average. Cadmium varied less among the countries: average 
urinary cadmium levels in Polish and Slovak mothers were respectively 1.9 and 1.7 times higher 
than the European average. In Romania and Hungary average cotinine levels were respectively 
2.4 and 2.2 times higher than the European average reflecting the weak anti-smoking legislation 
in these countries. Swedish children had on average 3 times higher urinary MBzP levels than the 
average European value. Slovak children had almost twice the average European biomarker 
concentrations of DEHP metabolites, while Polish children showed the highest average levels of 
MnBP and MiBP. Average MEP levels in Spain were 6 times higher than the European average. 
The heat map (Figure 2) showed that biomarker data from mothers and children clustered 
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together except in Czech Republic and Slovakia. Overall the biomarker clustering followed 
geographical grouping. The South European countries (ES, PT) clustered separately from the 
other countries; Eastern European countries (RO, HU, PL, CZ, SK) formed a further cluster; 
West European countries (DE, BE, LU, DK) also showed fairly good resemblance.  
Although the sampling frame of the European biomonitoring program differs from that of the US 
national program, the geometric means and P90 of COPHES/DEMOCOPHES are well in line 
with the results obtained in NHANES (Center for Disease Control (CDC) 2013; McDowell et al. 
2004) (Table 2). For MiBP, higher values were observed in Europe compared to the US (factor 
3-4), both in mothers and children (Table 2). Differences for other biomarkers were modest with 
a trend in Europe for lower biomarker concentrations of MBzP and MEP, higher concentrations 
of MnBP and DEHP and similar levels for cadmium and mercury. 
Available health-based guidance values allow to put the observed biomarker concentrations in a 
risk context. Few participants exceeded these values (Table 2). The P90 of the biomarker values 
are far below the guidance values, only for urinary cadmium P90 of mothers and children were 
within a factor two of the concentration below which no risk for adverse health effects is 
expected (Schulz et al. 2012) and for mercury they are below a factor three.  
Discussion 
This first Europe-wide program provides biomarker data from mothers and children of 17 
European countries. Since we recruited in one rural and one urban area per country, our sample 
was not representative for the EU population.Yet, the recruited sample had a similar smoking 
behavior as the average European population (Currie 2010). Also, the countries ranked for their 
reported fish consumption according to national statistics (FAO,2008). The educational level of 
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the participants was skewed towards a higher educational level. The study design allowed to 
conclude that exposure to mercury, cadmium, phthalates, and nicotine is widespread in the 
European population.  
Differences in environment and life style influenced individual biomarker values and country 
specific averages. If we compared average levels between countries, the biomarker patterns 
varied according to geographic trends. Yet, few study participants exceeded the available health-
based guidance values. The major strength of our study is comparable data from 17 European 
countries produced through a harmonized process including the use of a commonly developed 
protocol, intensive training and capacity building for field work, chemical analyses, reporting 
and communication, as well as stringent quality control programs for chemical and data analysis. 
This allowed us to measure both well-known pollutants such as cadmium, cotinine or mercury 
and new emerging chemicals such as phthalates.   
Our current study identified younger children as more exposed to phthalates (except MEP), 
cotinine and mercury. These results are in line with US data for exposure to phthalates (Silva et 
al.,2004) and ETS (Bernert et al.,2010). The underlying reasons cannot be derived from this 
study but may be explained by higher exposure relative to body size through inhalation of dust or 
food intake; by typical exposure patterns in children, e.g. contact with toys, more time spent on 
the floor, more frequent hand-mouth contact; or by differences in metabolism. Additionally, the 
higher cotinine levels in younger children might be due to the fact that they spend more time at 
home, and thus may be more exposed to nicotine, since smoking in public buildings is much 
more controlled than in private homes. We observed a significant influence of social class 
(represented by the highest educational level within the family) on each of the biomarker levels 
even after adjustment for confounders and significant covariates: mercury level in hair increased 
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in children and mothers if social class was higher, while cotinine, cadmium, phthalate 
metabolites were lower with increasing educational level of the family. Possibly, underlying life-
style factors that vary with socio-economic status, and were not considered in the questionnaires, 
may account for these findings. These associations between social class and biomarker 
concentrations are in line with US data (Tyrrell et al. 2013) and may partly be mediated by 
smoking, occupation and diet (fish consumption, local food, convenience food). Our findings, 
like others, thus indicate that public health remediation measures to decrease environmental 
exposure and disease burden within a society should be stratified according to age groups and 
social strata within the population.  
Fish consumption and social status were identified as important and independent determinants of 
mercury levels, both in mothers and children. This is in line with results from several populations 
with moderate to high fish consumption (Deroma et al. 2013). Mercury levels in children and in 
women of childbearing age are important parameters to monitor since pre- and postnatal mercury 
exposure, even at low levels, has adverse neurodevelopmental effects (Karagas et al. 2012). 
Although several high fish consuming countries such as France, Finland, Lithuania, Malta 
and Italy are not participating in DEMOCOPHES, at present, 1.4% of the children and 3.4% of 
the mothers in our study population had mercury levels above the JECFA/WHO provisional 
threshold value of 2.3 µg/g hair. This proportion differs considerably by country with 0% of 
participants exceeding the threshold in most northern and central European countries and up to 
33% of the mothers with levels above the safe dose in countries with high fish consumption with 
implications for loss of IQ points and costs (Bellanger et al. 2013). If these data urge policy 
makers to take actions, current biomarker concentrations can be used as baseline for follow-up, 
both for the exposure of the population and the environment. The major exposure route for 
16 
DEHP is food (Koch and Calafat 2009). Therefore, we were not surprised to find an association 
between DEHP metabolites with chewing gum and ice cream consumption. Most probably, these 
two food items are not specific sources, but rather represent predilection for flavored, packed, or 
processed food, and thus may be proxies for convenience food. The association between urinary 
MBzP and PVC materials in the home is in accordance with recent findings in children 
(Carlstedt et al. 2012). Although high molecular weight phthalates like DEHP are the major 
phthalates used in PVC, no association was found between the presence of PVC at home and 
urinary DEHP metabolites. Given the facts that DEHP exposure is dominated by foodstuff (Koch 
et al. 2013) and that DEHP house dust does not correlate with DEHP body burden (Becker et al. 
2004), a significant correlation was not really expected. The lower levels of DEHP metabolites 
and MnBP in mothers that were high PCP users was not expected and may relate to cross 
correlation with other personal habits. The relative levels of phthalate metabolites differ 
substantially among countries which points to different sources, products on the market or 
behavior characteristics. Despite legal restrictions on the use of DEHP, di-n-butyl phthalate, and 
diisobutyl phthalate as imposed by EU directives, these compounds are still ubiquitous in 
Europeans. They are short-lived in the body, implying that exposures to these compounds are 
still part of current daily life. Diethylphthalate, one of the principal phthalates in cosmetic 
products (Koch and Calafat 2009), is not yet restricted. High levels of its metabolite MEP were 
found.  
The health impact of cigarette smoking is well documuented (U.S.Department of Health and 
Human Services 2004). The home environment appears to be the most important predictor of the 
cotinine levels in children. Further awareness of parents therefor is needed. The importance of 
anti-smoke legislation pays off as countries with a stronger legislation that was longer in place 
17 
showed the lowest cotinine levels (http://ec.europa.eu/health/tobacco/docs/ 
tobacco_overview2011_en.pdf). The effectiveness of anti-smoke legislation on health outcomes 
has been demonstrated on a population level (Cox et al. 2013).  
Conclusion 
This HBM study presents the first steps, for Europe as a whole, to register internal chemical 
exposures at individual level. Although the sampling protocol is not yet reprentative for the 
geographivcal distribution of the population in the country, the results show remarkable 
differences in the biomarker concentration profiles by country residence. Personal habits and life 
style are strong determinants of internal exposure. The harmonized protocols and stringent 
quality control measures ensure that these are true differences, not related to variability in 
protocols, analytical measurements, or interpretation. These data offer policy makers direct 
means to evaluate whether implementation of protective measures and legislations related to 
chemicals are adequate to protect health of the entire population or whether they need to be 
adjusted.  
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Table 1. Descriptive statistics of the study population. 
 Children Mothers 
 N Median (P25-P75) Min.-max. N Median (P25-P75) Min.-max. 
Age (years) 1844 8 (7,10) 5-12 1844 39 (35,42) 24 -52 
Urinary creatinine (mg/L) 1842 1053 (784,1426) 10-3120 1839 1163 (781,1618) 57-3670 
Body height (cm) 1819 135 (127,145) 98-170 1836 166 (161,170) 145-191 
Body weight (kg) 1820 30 (25,36) 14-81 1836 64 (58,72) 35-186 
Body-mass index (kg/m²) 1811 16.3 (14.9,18.2) 10.0-36.1 1833 23.2 (21.1,26.3) 14.7-62.2 
 Children Mothers 
 N Categories N (%) N Categories N (%) 
Gender 1844 Boy 
Girl 
912 (49.5%) 
932 (50.5%) 
1844 Woman 1844 (100%) 
Area of residence 1844 Rural 
Urban 
923 (50.1%) 
921 (49.9%) 
1844 as in children 
Highest educational level 
of the family 
1843 Primary (ISCED 0-2) 
Secondary (ISCED 3-4) 
Tertiary (ISCED 5-6) 
166 (9.0%) 
607 (32.9%) 
1070 (58.1%) 
1843 as in children 
Smoking habits 1844 Smoker 0 (0%) 1844 Daily smoker 283 (15.3%) 
  Non-smoker 1844 (100%)  Occasional smoker 106 (5.7%) 
     Former smoker 401 (21.7%) 
     Never smoker 1054 (57.2%) 
ETS at home 
(non-smokers only) 
1842 Daily 
Less than daily 
Never 
179 (9.7%) 
130 (7.1%) 
1533 (83.2%) 
1450 Yes 
No 
162 (11.2%) 
1288 (88.8%) 
ETS elsewhere 
(non-smokers only) 
1842 Yes 
No 
775 (42.1%) 
1067 (57.9%) 
1455 Yes 
No 
827 (56.8%) 
628 (43.2%) 
ETS in last 24 hours 
(non-smokers only) 
1840 Yes 
No 
232 (12.6%) 
1608 (87.4%) 
1450 Yes 
No 
164 (11.3%) 
1286 (88.7%) 
24 
 Children Mothers 
 N Categories N (%) N Categories N (%) 
Fish consumption  1844 Several times/week 442 (24.0%) 1844 Several times/week 483 (26.2%) 
(all types)  Once a week or less 1402 (76.0%)  Once a week or less 1361 (73.8%) 
Consumption of seafish 1840 Several times/week 
Once a week or less 
283 (15.4%) 
1557 (84.6%) 
1840 Several times/week 
Once a week or less 
294 (16.0%) 
1546 (84.0%) 
Consumption of shellfish 1820 Several times/week 
Once a week or less 
194 (10.7%) 
1626 (89.3%) 
1826 Several times/week 
Once a week or less 
355 (19.4%) 
1471 (80.6%) 
Consumption of fresh water 
fish 
1815 Several times/week 
Once a week or less 
248 (13.7%) 
1567 (86.3%) 
1818 Several times/week 
Once a week or less 
298 (16.4%) 
1520 (83.6%) 
Consumption of sea food 
products 
1811 Several times/month 
Once a month or less 
94 (5.2%) 
1717 (94.8%) 
1811 Several times/month 
Once a month or less 
154 (8.5%) 
1657 (91.5%) 
Consumption of ice cream 1821 Several times/week 
Once a week or less 
185 (10.2%) 
1636 (89.8%) 
1829 Several times/month 
Once a month or less 
536 (29.3%) 
1293 (70.7%) 
Consumption of chewing 
gum 
1662 Several times/week 
Once a week or less 
578 (34.8%) 
1084 (65.2%) 
1675 Several times/week 
Once a week or less 
626 (37.4%) 
1049 (62.6%) 
Use of personal care 
productsa 
1816 High or moderate 
Low  
822 (45.3%) 
994 (54.7%) 
1806 High 
Moderate or low 
861 (47.7%) 
945 (52.3%) 
PVC in house 1773 PVC in floors or walls 
No PVC 
342 (19.3%) 
1431 (80.7%) 
1773 as in children 
P25: 25th percentile; P75: 75th percentile; N: number; ISCED: International Standard Classification of Education; ETS: environmental 
tobacco smoke; PVC: polyvinyl chloride 
aUse of personal care products (PCP) is calculated as a score based on the frequency (never to daily) of 9 PCP groups (make-up, eye 
make-up, shampoo, hair styling products, body lotions and creams, fragrances, deodorant, massage oil and nail polish). 
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Table 2. European exposure values in children and mothers in COPHES/DEMOCOPHES study.  
Biomarker of 
exposure	  
COPHES/DEMOCOPHES study NHANESd 
 N % >LOQa GM 
(95% CI)b 
P90 
(95% CI)b 
N (%) exceeding 
guidance valuec 
Period N GM 
(95% CI) 
P90 
(95% CI) 
Mercury in hair 
(µg/g) 
1836 85.9% 0.145 
(0.139,0.151) 
0.800 
(0.698,0.917) 
JECFA: N=25 (1.4%) 1999-
2000 
838 0.12 
(0.10,0.12) 
0.41 
Urinary cotinine 
(µg/L) 
1818 57.6% 0.80 
(0.76,0.84) 
4.90 
(3.90,6.16) 
- - - - - 
Urinary cadmium 
(µg/L) 
1698 70.1% 0.071 
(0.069,0.074) 
0.220 
(0.209,0.232) 
HBM-I: N=6 (0.4%) 
HBM-II: N=0 (0.0%)  
BE: N=0 (0.0%) 
2009-
2010 
415 0.057 
(0.053,0.061) 
0.130 
(0.120,0.160) 
Urinary DEHP  
metabolites  
(µg/L) (5) 
1816 85.6% 47.6 
(46.0,49.3) 
137 
(126,150) 
HBM-I: N=12 (0.6%) 
BE: N=53 (2.9%) 
2009-
2010 
415 MEHP: 1.64 (1.45,1.85) 
5OH-MEHP: 15.0 (13.2,17.1) 
5oxo-MEHP: 9.87 (8.72,11.0) 
∑(GM)=26.5 
Urinary MEP 
(µg/L) 
1816 98.0% 34.4 
(32.8,36.0) 
159 
(138,183) 
BE: N=0 (0.0%) 2009-
2010 
415 35.2 
(31.2,39.8) 
151 
(114,207) 
Urinary MBzP 
(µg/L) 
1816 95.2% 7.1 
(6.8,7.5) 
27.8 
(25.2,30.6) 
BE: N=0 (0.0%) 2009-
2010 
415 11.6 
(9.51,14.1) 
63.9 
(47.4,76.8) 
Urinary MnBP 
(µg/L) 
1355 99.9% 34.8 
(33.5,36.2) 
95.5 
(87.3,104.5) 
- 2009-
2010 
415 21.7 
(19.0,24.8) 
83.8 
(59.6,121) 
Urinary MiBP 
(µg/L) 
1355 99.8% 45.4 
(43.6,47.3) 
131 
(117,147) 
- 2009-
2010 
415 10.2 
(9.10,11.4) 
35.7 
(28.8,46.9) 
Mercury in hair 
(µg/g) 
1839 90.5% 0·225 
(0·216,0·234) 
1.200 
(1.068,1.349) 
JECFA: N=62 (3.4%) 1999-
2000 
1726 0.20 
(0.16,0.24) 
1.11 
Urinary cotinine 
(µg/L) 
1800 62.4% 2.75 
(2.41,3.14) 
1182 
(974,1434) 
- - - - - 
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Biomarker of 
exposure	  
COPHES/DEMOCOPHES study NHANESd 
 N % >LOQa GM 
(95% CI)b 
P90 
(95% CI)b 
N (%) exceeding 
guidance valuec 
Period N GM 
(95% CI) 
P90 
(95% CI) 
Urinary cadmium 
(µg/L) 
1685 93.8% 0.219 
(0.211,0.228) 
0.620 
(0.580,0.663) 
HBM-I: N=49 (2.9%) 
HBM-II: N=0 (0.0%) 
BE: N=26 (1.5%) 
2009-
2010 
1450 0.188 
(0.172,0.206) 
0·740 
(0·620,0·880) 
Urinary DEHP  
metabolites  
(µg/L) e 
1800 81.6% 29.2 
(28.1,30.3) 
91 
(84,100) 
HBM-I: N=19 (1.0%) 
BE: N=28 (1.5%) 
2009-
2010 
1350 MEHP: 1.39 (1.21,1.60) 
5OH-MEHP: 11.0 (9.58,12.8) 
5oxo-MEHP: 7.09 (6.17,8.14) 
∑(GM)=19.5 
Urinary MEP 
(µg/L) 
1800 95.2% 48.2 
(45.6,51.0) 
252 
(221,287) 
BE: N=0 (0.0%) 2009-
2010 
1350 67.8 
(60.3,76.4) 
548 
(392,675) 
Urinary MBzP 
(µg/L) 
1800 91.8% 4.5 
(4.3,4.7) 
17·7 
(16.1,19.5) 
BE: N=0 (0.0%) 2009-
2010 
1350 6.04 
(5.38,6.77) 
29.3 
(24.5,36.9) 
Urinary MnBP 
(µg/L) 
1347 99.4% 23.9 
(23.0,24.9) 
66.2 
(60.5,72.4) 
- 2009-
2010 
1350 14.7 
(13.1,16.5) 
57.7 
(52.7,63.9) 
Urinary MiBP 
(µg/L) 
1347 99.4% 30.1 
(28.9,31.4) 
88 
(81,96) 
- 2009-
2010 
1350 7.50 
(6.68,8.43) 
29.1 
(25.3,33.5) 
LOQ: limit of quantification; N: number; GM: geometric mean; 95% CI: 95% confidence interval; P90: 90th percentile; DEHP: di(2-
ethylhexyl)phthalate; MEP: mono-ethyl phthalate; MBzP: mono-benzyl phthalate; MnBP: mono-n-butyl phthalate; MiBP: mono-iso-butyl 
phthalate; JECFA: Joint FAO/WHO Expert Committee on Food Additives; HBM-I human biomonitoring value I; HBM-II: human biomonitoring 
value II; BE: biomonitoring equivalent; ∑(GM): sum of geometric means of MEHP, 5OH-MEHP and 5oxo-MEHP.  
aLimits of quantification (LOQs) ranged between 0.001 to 0.137 µg/g for mercury in hair, 0.1-1.2 µg/L for urinary cotinine, 0.001-0.2 µg/L for 
urinary cadmium, 0.3-3.9 µg/L for urinary MEHP, 0.1-9.2 µg/L for urinary 5OH-MEHP, 0.1-6.2 µg/L for urinary 5oxo-MEHP, 0.5-11 µg/L for 
urinary MEP, 0.2-5 µg/L for urinary MBzP, 0.5-4.4 µg/L for urinary MnBP and 0.5-4.9 µg/L for urinary MiBP. bGeometric means and 90th 
percentiles are weighed but not adjusted for confounders (see methods). cHealth-based exposure values are available for mercury: JECFA 
guideline = 2.3 µg/g (Joint Expert Committee on Food Additives 2003); cadmium: HBM-I in children = 0.5 µg/L; HBM-II in children = 1 µg/L; 
27 
HBM-I in adults = 1.0 µg/L; HBM-II in adults = 4.0 µg/L (Schulz et al. 2012); BE in children and in mothers = 1.2 µg/L (Hays et al. 2008); 
phthalate metabolites: HBM-I value for DEHP metabolites are based on the sum of 5OH-MEHP and 5oxo-MEHP and equal 500 µg/L in children 
and 300 µg/L in adults (Schulz et al. 2012); BE’s for DEHP metabolites are based on the sum of MEHP, 5OH-MEHP and 5oxo-MEHP and equal 
260 µg/L in children and in mothers (Aylward et al. 2009a); BE for MEP in mothers and children = 18 mg/L (Aylward et al. 2009b); BE for 
MBzP in children and adults = 3.8 mg/L (Aylward et al. 2009b). dNHANES: data of urinary cadmium and urinary phthalate metabolites from ‘The 
Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, March 2013’ (Center for Disease Control (CDC) 
2013); data of mercury in hair: from McDowell et all. (McDowell et al. 2004) Data of COPHES/DEMOCOPHES children are compared with 
NHANES subgroup ‘Age group 6-11 years’; data of COPHES/DEMOCOPHES mothers are compared with NHANES subgroup ‘Females’.   
eUrinary DEHP metabolites: sum of MEHP, 5OH-MEHP and 5oxo-MEHP. 
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Table 3. Determinants of exposure to urinary phthalate metabolites (µg/L): multiple regression models in children. 
  Estimate (95% CI) for change (multiplicative factor) 
Parameters Strata DEHP MEP MBzP MnBP MiBP 
Ageb 5-8 years  
9-11 years 
1.19 (1.11, 1.27) 
1.00 
1.15 (1.04, 1.26) 
1.00 
1.15 (1.06, 1.26) 
1.00 
1.15 (1.07, 1.24) 
1.00 
1.19 (1.10, 1.28) 
1.00 
Genderb boys 
girls 
ns ns ns 0.91 (0.85, 0.98) 
1.00 
0.92 (0.85, 0.99) 
1.00 
Urinary creatinine levelb 300-900 mg/L 
900-1500 mg/L 
1500-3000 mg/L 
0.46 (0.42,0.51) 
0.75 (0.69, 0.83) 
1.00 
0.41 (0.36, 0.47) 
0.68 (0.61, 0.77) 
1.00 
0.41 (0.37, 0.47) 
0.69 (0.62, 0.78) 
1.00 
0.45 (0.41, 0.50) 
0.73 (0.66, 0.81) 
1.00 
0.45 (0.40, 0.50) 
0.72 (0.65, 0.80) 
1.00 
Urine sampling period <10 hours 
10-11 hours 
≥11 hours 
ns 1.20 (1.06, 1.35) 
1.14 (1.02, 1.29) 
1.00 
ns ns ns 
Morning urine yes 
no 
ns ns 1.98 (1.17, 3.36) 
1.00 
ns ns 
Educational level of the 
family 
primary 
secondary 
tertiary 
ns 0.91 (0.81, 1.03) 
0.89 (0.82, 0.97) 
1.00 
ns 0.91 (0.81, 1.03) 
0.89 (0.82, 0.97) 
1.00 
ns 
Use of personal care 
productsa 
moderate to high use 
low use 
ns 1.24 (1.13, 1.37) 
1.00 
ns ns 1.13 (1.03, 1.23) 
1.00 
Ice cream consumption several times/week 
once/week or less 
1.12 (1.01, 1.25) 
1.00 
ns 1.18 (1.02, 1.36) 
1.00 
ns ns 
Gum consumption several times/week 
once/week or less 
1.10 (1.02, 1.18) 
1.00 
ns ns ns ns 
PVC in floors/walls yes 
no 
ns ns 1.50 (1.34, 1.68) 
1.00 
1.19 (1.08, 1.32) 
1.00 
1.22 (1.09, 1.35) 
1.00 
aUse of personal care products (PCP) is calculated as a score based on the frequency (never to daily) of 9 PCP groups (make-up, eye make-up, 
shampoo, hair styling products, body lotions and creams, fragrances, deodorant, massage oil and nail polish). bThe confounders urinary creatinine 
level, gender, and age were forced in the multiple regression models, even if not significant.
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Table 4. Determinants of exposure to urinary phthalate metabolites (µg/L): multiple regression models in mothers. 
  Estimate (95% CI) for change (multiplicative factor) 
Parameters Strata DEHP MEP MBzP MnBP MiBP 
Ageb ≤35 years 
35-40 years 
>40 years 
ns ns ns 0.81 (0.73, 0.89) 
0.93 (0.86, 1.01) 
1.00 
ns 
Body-mass index normal weight 
overweight 
obese 
ns ns ns 1.15 (1.02, 1.29) 
1.09 (0.96, 1.24) 
1.00 
ns 
Urinary creatinine levelb 300-900 mg/L 
900-1500 mg/L 
1500-3000 mg/L 
0.35 (0.32, 0.38) 
0.62 (0.57, 0.68) 
1.00 
0.32 (0.28, 0.37) 
0.63 (0.55, 0.72) 
1.00 
0.33 (0.30, 0.37) 
0.59 (0.54, 0.65) 
1.00 
0.35 (0.32, 0.38) 
0.60 (0.55, 0.66) 
1.00 
0.38 (0.35, 0.41) 
0.61 (0.56, 0.67) 
1.00 
Urine sampling period <7 hours 
7-9 hours 
≥9 hours 
0.87 (0.79, 0.97) 
0.97 (0.88, 1.06) 
1.00 
ns ns ns ns 
Educational level of the 
family 
primary 
secondary 
tertiary 
1.20 (1.05, 1.37) 
1.04 (0.96, 1.13) 
1.00 
ns ns ns 1.09 (0.97, 1.23) 
1.11 (1.02, 1.21) 
1.00 
Use of personal care 
productsa 
high use 
moderate to low use 
0.91 (0.84, 0.98) 
1.00 
1.40 (1.25, 1.56) 
1.00 
ns 0.92 (0.86, 0.99) 
1.00 
ns 
Ice cream consumption several times/month 
once/month or less 
ns ns 1.13 (1.03, 1.24) 
1.00 
1.10 (1.01, 1.19) 
1.00 
ns 
Gum consumption several times/week 
once/week or less 
ns 1.19 (1.06, 1.34) 
1.00 
ns ns ns 
PVC in floors/walls yes 
no 
ns ns 1.32 (1.19, 1.47) 
1.00 
ns 1.15 (1.04, 1.26) 
1.00 
Renovation in house yes 
no 
ns ns ns ns 1.08 (1.00, 1.16) 
1.00 
ns: not significant; abbreviations biomarkers: see Table 2. 
aUse of personal care products (PCP) is calculated as a score based on the frequency (never to daily) of 9 PCP groups (make-up, eye make-up, 
shampoo, hair styling products, body lotions and creams, fragrances, deodorant, massage oil and nail polish). bThe confounders urinary creatinine 
level and age were forced in the multiple regression models, even if not significant 
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Figure legends 
Figure 1. Overview of  geometric means (95% CI) of biomarker concentrations (µg/L) in 
children and mothers of the participating countries.  Country codes: Belgium (BE); Switzerland 
(CH), Cyprus (CY), Czech Republic (CZ), Germany (DE), Denmark (DK), Spain (ES), Hungary 
(HU), Ireland (IE), Luxembourg (LU), Poland (PL), Portugal (PT), Romania (RO), Sweden (SE), 
Slovenia (SI), Slovak Republic (SK) and United Kingdom (UK). Abbeviations biomarkers: see 
Table 2.All data in children are adjusted for age and gender; urinary metabolites are additionally 
adjusted for urinary creatinine; all data in mothers are adjusted for age; urinary metabolites are 
additionally adjusted for urinary creatinine; urinary cadmium is additionally adjusted for 
smoking. Light grey: GM of country significantly below European GM. Dark grey: GM of 
country is significantly above European GM. White: no significant difference between GM of 
country and European GM. NA: no biomarker data available. European GMs: see Table 2. 
Figure 2. Heat map showing clustering of biomarkers (dendrogram to the left side) and 
clustering of countries (dendrogram at the top). Red and blue intensities indicate fold increases 
respectively decreases (expressed as log2) in country specific biomarker concentrations adjusted 
for age and gender relative to the European geometric mean. Country codes: see Figure 1. 
Country codes followed by M present concentrations in mothers, countrycodes followed by C 
present concentrations in children. White rectangles: missing data. 
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Figure 1. 
 
  
CHILDREN BE CH CY CZ DE DK ES HU IE LU PL PT RO SE SI SK UK 
Mercury 0.204 (0.172, 
0.241) 
0.076 
(0.065, 
0.090) 
0.326 
(0.257, 
0.413) 
0.098 
(0.083, 
0.116) 
0.055 
(0.046, 
0.065) 
0.250 
0.211, 
0.295) 
0.884 
(0.747, 
1.046) 
0.025  
(0.021, 
0.029) 
0.097  
(0.082, 
0.114) 
0.181 
(0.142, 
0.229) 
0.070 
(0.060, 
0.083) 
1.033 
(0.873, 
1.222) 
0.085 
(0.072, 
0.101) 
0.181 
(0.153, 
0.214) 
0.169 
(0.142, 
0.200) 
0.092 
(0.078, 
0.109) 
0.192 
(0.163, 
0.228) 
Cadmium 0.046 (0.040, 
0.052) 
0.081 
(0.071, 
0.092) 
0.114 
0.096, 
0.261) 
0.117 
(0.104, 
0.133) 
NA 0.024 
(0.021, 
0.027) 
0.047 
(0.041, 
0.053) 
0.129 
(0.113, 
0.146) 
0.068 
(0.060, 
0.077) 
0.154 
(0.129, 
0.184) 
0.134 
(0.118, 
0.152) 
0.045 
(0.039, 
0.051) 
0.026 
(0.023, 
0.029) 
0.090 
(0.079, 
0.103) 
0.077 
(0.068, 
0.087) 
0.144 
(0.127, 
0.163) 
0.167 
(0.147, 
0.191) 
Cotinine 0.629 (0.517, 
0.766) 
0.508 
(0.418, 
0.619) 
0.842 
(0.638, 
1.111 
1.602 
(1.316, 
1.950) 
0.305 
(0.251, 
0.371) 
0.658 
(0.541, 
0.801) 
1.485 
(1.219, 
1.810) 
1.776 
(1.460, 
2.161) 
0.708 
(0.582, 
0.862) 
0.397 
(0.301, 
0.524) 
1.568 
(1.288, 
1.909) 
1.093 
(0.897, 
1.333) 
1.942 
(1.943, 
1.597) 
0.202 
(0.165, 
0.246) 
0.529 
(0.434, 
0.644) 
1.085 
(0.892, 
1.320) 
0.661 
(0.542, 
0.806) 
DEHP 37.3 (32.9, 
42.2) 
28.1 
(24.9, 
31.9) 
25.0 
(21.0, 
29.8) 
71.1 
(62.7, 
80.5) 
39.5 
(34.9, 
44.8) 
40.9 
(36.1, 
46.4) 
73.4 
(64.7, 
83.2) 
58.7 
(51.8, 
66.5) 
59.6 
(52.6, 
67.5) 
25.8 
(21.7, 
30.8) 
76.4 
(67.4, 
86.6) 
48.2 
(42.5, 
54.6) 
74.0 
(65.4, 
83.8) 
49.9 
(43.9, 
56.6) 
46.3 
(40.8, 
53.4) 
82.7 
(73.0, 
93.7) 
37.5 
(33.0, 
42.5) 
MEP 26.7 (22.3, 
32.0) 
19.7 
(16.5, 
23.6) 
41.2 
(31.9, 
53.1) 
34.4 
(28.7, 
41.1) 
23.1 
(19.3, 
27.7) 
22.1 
(18.5, 
26.5) 
208.3 
(173.7, 
249,8) 
45.4 
(37.9, 
54.3) 
42.5 
(35.5, 
50.9) 
26.8 
(20.8, 
34.6) 
46.9 
(39.1, 
56.2) 
50.2 
(41.8, 
60.2) 
34.8 
(29.1, 
41.7) 
33.3 
(27.8, 
40.0) 
40.2 
(33.5, 
48.1) 
37.5 
(31.3, 
44.9) 
16.9 
(14.1, 
20.3) 
MBzP 9.0 (7.5, 
10.6) 
5.1 
(4.3, 
6.1) 
3.7 
(2.9, 
4.7) 
9.1 
(7.6, 
10.8) 
6.6 
(5.5, 
7.8) 
8.0 
(6.7, 
9.4) 
14.6 
(12.3, 
17.3) 
7.3 
(6.2, 
8.7) 
5.9 
(5.0, 
7.0) 
5.2 
(4.1, 
6.6) 
9.3 
(7.9, 
11.1) 
8.1 
(6.8, 
9.6) 
4.1 
(3.5, 
4.9) 
23.1 
(19.4, 
27.5) 
7.9 
(6.6, 
9.4) 
7.9 
(6.6, 
9.4) 
4.2 
(3.5, 
4.9) 
MnBP 39.4 (34.9, 
44.6) 
20.1 
(17.8, 
22.8) 
20.6 
(17.3, 
24.6) 
NA 46.4 
(41.0, 
52.5) 
33.6 
(29.7, 
38.1) 
52.7 
(46.5, 
59.7) 
NA 28.5 
(25.2, 
32.2) 
28.2 
(23.7, 
33.6) 
90.4 
(80.0, 
102.3) 
33.3 
(29.4, 
37.7) 
43.2 
(38.2, 
48.8) 
NA 38.0 
(33.5, 
42.9) 
NA 26.4 
(23.3, 
29.9) 
MiBP 59.2 (51.9, 
67.5) 
20.5 
(18.0, 
23.4) 
51.8 
(43.0, 
62.3) 
NA 41.4 
(36.3, 
47.2) 
62.2 
(54.5, 
71.0) 
63.8 
(55.9, 
72.9) 
NA 45.4 
(39.8, 
51.7) 
36.9 
(30.6, 
44.4) 
108.3 
(95.0, 
123.5) 
40.3 
(35.3, 
46.1) 
51.1 
(44.8, 
58.3) 
NA 55.0 
(48.2, 
62.7) 
NA 30.3 
(26.5, 
34.6) 
MOTHERS BE CH CY CZ DE DK ES HU IE LU PL PT RO SE SI SK UK 
Mercury 0.368 (0.313, 
0.431) 
0.153 
(0.131, 
0.180) 
0.462 
(0.369, 
0.578) 
0.156 
(0.133, 
0.183) 
0.107 
(0.092, 
0.126) 
0.391 
(0.333, 
0.458) 
1.486 
(1.267, 
1.744) 
0.039 
(0.033, 
0.045) 
0.162 
(0.139, 
0.190) 
0.387 
(0.308, 
0.485) 
0.135 
(0.116, 
0.159) 
1.200 
(1.023, 
1.406) 
0.100 
(0.085, 
0.117) 
0.252 
(0.215, 
0.295) 
0.255 
(0.217, 
0.299) 
0.132 
(0.112, 
0.154) 
0.153 
(0.130, 
0.180) 
Cadmium 0.224 (0.197, 
0.255) 
0.224 
(0.197, 
0.255) 
0.183 
(0.153, 
0.219) 
0.259 
(0.228, 
0.295) 
 NA 0.132 
(0.116, 
0.150) 
0.212 
(0.187, 
0.241) 
0.183 
(0.161, 
0.207) 
0.296 
(0.261, 
0.336) 
0.249 
(0.208, 
0.298) 
0.453 
(0.399, 
0.514) 
0.186 
(0.164, 
0.211) 
0.187 
(0.164, 
0.212) 
0.175 
(0.154, 
0.199) 
0.289 
(0.255, 
0.329) 
0.306 
(0.269, 
0.348) 
0.267 
(0.234, 
0.304) 
Cotinine 1.257 (0.736, 
2.147) 
0.844 
(0.493, 
1.446) 
2.825 
(1.329, 
6.002) 
3.773 
(2.211, 
6.441) 
1.005 
(0.588, 
1.717) 
1.871 
(1.091, 
3.209) 
9.586 
(5.597, 
16.42) 
7.187 
(4.209, 
12.27) 
3.863 
(2.266, 
6.585) 
0.557 
0.260, 
1.193) 
6.219 
(3.644, 
10.61) 
10.92 
(6.401, 
18.64) 
14.92 
(8.702, 
25.57) 
1.803 
1.056, 
3.080) 
1.790 
(1.048, 
3.058) 
2.819 
(1.653, 
4.809) 
0.843 
(0.489, 
1.452) 
DEHP 21.7 (19.0, 
24.8) 
20.4 
(17.8, 
23.3) 
16.8 
(13.9, 
20.3) 
37.3 
(32.6, 
42.6) 
21.1 
(18.5, 
24.1) 
24.0 
(21.0, 
27.4) 
43.4 
(38.0, 
49.6) 
34.0 
(29.7, 
38.8) 
32.3 
(29.7, 
38.8) 
15.9 
(13.2, 
19.3) 
43.9 
(38.4, 
50.2) 
37.2 
(32.6, 
42.5) 
51.5 
(45.0, 
58.9) 
28.4 
(24.8, 
32.4) 
28.1 
(24.6, 
32.1) 
39.4 
(34.5, 
45.0) 
15.5 
(13.5, 
17.8) 
MEP 37.1 (30.1, 
45.8) 
31.2 
(25.2, 
38.5) 
87.7 
(65.2, 
117.9) 
59.2 
(48.0, 
73.0) 
38.5 
(31.2, 
47.6) 
37.3 
(30.2, 
46.1) 
160.0 
(129.5, 
197.6) 
50.9 
(41.2, 
62.8) 
55.2 
(44.8, 
68.1) 
36.4 
(27.0, 
49.1) 
42.5 
(34.5, 
52.5) 
55.9 
(45.3, 
68.9) 
44.2 
(35.8, 
54.7) 
46.5 
(37.7, 
57.4) 
46.8 
(37.9, 
57.8) 
52.2 
(42.3, 
64.4) 
27.4 
(22.1, 
33.9) 
MBzP 6.5 (5.6, 
7.7) 
3.9 
(3.3, 
4.6) 
2.4 
(1.9, 
3.0) 
4.7 
(4.0, 
5.6) 
4.5 
(3.8, 
5.2) 
4.5 
(3.8, 
5.2) 
8.5 
(7.2, 
9.9) 
4.3 
(3.7, 
5.1) 
3.4 
(2.9, 
4.0) 
3.6 
(2.8, 
4.5) 
4.5 
(3.9, 
5.3) 
5.6 
(4.8, 
6.6) 
2.5 
(2.1, 
2.9) 
13.8 
(11.8, 
16.2) 
4.4 
(3.8, 
5.2) 
4.4 
(3.8, 
5.2) 
1.7 
(1.5, 
2.0) 
MnBP 30.5 (27.1, 
34.4) 
13.9 
(12.3, 
15.7) 
16.1 
(13.6, 
19.1) 
 NA 29.7 
(26.4, 
33.5) 
21.6 
(19.2, 
24.4) 
30.8 
(27.3, 
34.7) 
NA 20.2 
(18.0, 
22.8) 
18.3 
(15.4, 
21.7) 
48.2 
(42.8, 
54.4) 
22.3 
(19.8, 
25.1) 
27.1 
(24.0, 
30.6) 
 NA 23.8 
(21.1, 
26.8) 
NA  13.1 
(11.6, 
14.9) 
MiBP 38.6 (34.1, 
43.6) 
14.4 
(12.7, 
16.3) 
43.7 
(36.8, 
52.0) 
 NA 24.6 
(21.8, 
27.8) 
41.6 
(36.7, 
47.1) 
37.0 
(32.7, 
41.8) 
NA  26.5 
(23.4, 
29.9) 
21.1 
(17.7, 
25.1) 
53.6 
(47.4, 
60.6) 
28.4 
(25.1, 
32.1) 
34.7 
(30.6, 
39.2) 
 NA 34.9 
(30.8, 
39.4) 
 NA 17.6 
(15.5, 
19.9) 
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